ANI Pharmaceuticals, Inc.

NasdaqGM ANIP

ANI Pharmaceuticals, Inc. Receivables for the quarter ending September 30, 2024: USD 196.36 M

ANI Pharmaceuticals, Inc. Receivables is USD 196.36 M for the quarter ending September 30, 2024, a 9.80% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.
  • ANI Pharmaceuticals, Inc. Receivables for the quarter ending September 30, 2023 was USD 178.84 M, a 27.35% change year over year.
  • ANI Pharmaceuticals, Inc. Receivables for the quarter ending September 30, 2022 was USD 140.43 M, a 31.60% change year over year.
  • ANI Pharmaceuticals, Inc. Receivables for the quarter ending September 30, 2021 was USD 106.71 M, a 27.43% change year over year.
  • ANI Pharmaceuticals, Inc. Receivables for the quarter ending September 30, 2020 was USD 83.75 M, a 18.45% change year over year.
Key data
Date Receivables Inventory Goodwill Total Assets
Market news
Loading...
NasdaqGM: ANIP

ANI Pharmaceuticals, Inc.

CEO Mr. Nikhil Lalwani
IPO Date May 5, 2000
Location United States
Headquarters 210 Main Street West
Employees 642
Sector Health Care
Industries
Description

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Similar companies

IRWD

Ironwood Pharmaceuticals, Inc.

USD 3.65

-3.18%

NBIX

Neurocrine Biosciences, Inc.

USD 139.51

-2.46%

ALKS

Alkermes plc

USD 28.50

0.53%

PCRX

Pacira BioSciences, Inc.

USD 20.55

-2.74%

PBH

Prestige Consumer Healthcare Inc.

USD 75.78

1.54%

PAHC

Phibro Animal Health Corporation

USD 20.28

0.05%

COLL

Collegium Pharmaceutical, Inc.

USD 33.18

-1.80%

AMPH

Amphastar Pharmaceuticals, Inc.

USD 38.48

1.48%

PROC

Procaps Group S.A.

USD 1.76

7.98%

StockViz Staff

January 15, 2025

Any question? Send us an email